LMAT - LeMaitre Vascular: Balance Sheet Expansion Adds ~$2 Per Share Value To Date
- LeMaitre Vascular continues to present as a compelling investment case, with the economic pillars for long-term growth.
- Management expanded the balance sheet in FY2019, and have since put it to effective use in FY2020.
- Several acquisitions completed last year are already contributing nicely to the top and bottom lines.
- We see a fair value of $67, based on a blend of valuation scenarios that point to ~40-50% upside potential.
- Here LMAT is benchmarked against an already outperforming portfolio of US listed healthcare equities across metrics to justify investment.
For further details see:
LeMaitre Vascular: Balance Sheet Expansion Adds ~$2 Per Share Value To Date